Related Experiment Video
Updated: May 13, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Canakinumab in pediatric rheumatic diseases
Nico M Wulffraat1, Patricia Woo
1University medical Center Utrecht, Department Pediatric Rheumatology, Utrecht, Netherlands. N.wulffraat@umcutrecht.nl
Expert Opinion on Biological Therapy
|March 5, 2013
Summary
Canakinumab, a new interleukin-1β inhibitor, offers effective treatment for cryopyrin-associated periodic fever syndrome and systemic juvenile idiopathic arthritis. This biological therapy provides remission for children with these severe arthritis forms.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Severe childhood arthritis forms, including cryopyrin-associated periodic fever syndrome (CAPS) and systemic juvenile idiopathic arthritis (sJIA), have historically shown resistance to conventional therapies and anti-tumour necrosis factor agents.
- Novel monoclonal antibodies are emerging as significant advancements in treating these challenging conditions.
- Canakinumab, a monoclonal antibody targeting interleukin-1β (IL-1β), demonstrates specific efficacy in arthritis with systemic features.
Purpose of the Study:
- To review the clinical features and current treatment landscape of CAPS and sJIA.
- To provide an overview of existing IL-1 inhibitors.
- To evaluate clinical trial data for canakinumab in treating CAPS and sJIA.
Main Methods:
- Review of clinical features and treatment history for CAPS and sJIA.
- Synthesis of information on current IL-1 inhibitors.
- Evaluation of clinical trial outcomes for canakinumab in pediatric arthritis patients.
Main Results:
- Canakinumab has shown specific efficacy in treating CAPS and sJIA.
- Significant treatment advancements have been observed in the last decade for children with CAPS and sJIA.
- Patients treated with canakinumab have achieved remission during therapy.
Conclusions:
- Canakinumab represents a major therapeutic advance for children with CAPS and sJIA.
- Outcomes for anti-IL-1β (canakinumab) and anti-IL-6 therapies in sJIA are comparable, with no clear preference for one over the other.
- The development of targeted biological therapies has transformed the management of severe pediatric inflammatory conditions.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...